
Chip design methodology
The chip design methodology improves cybersecurity of low-power devices such as smart cards. Partner with us to accelerate development through licensing or co-development.
Researchers at the University of Melbourne have developed new technologies that help to solve pressing challenges. You can license these technologies for your business, organisation or government department. We have technologies that can be used for the environment, information and communication, diagnostics, biotechnology, engineering and more. Browse the University's technologies that are available for licensing, and keep up to date with technologies that have been recently licensed.
The chip design methodology improves cybersecurity of low-power devices such as smart cards. Partner with us to accelerate development through licensing or co-development.
Microalgae produce components that have commercial use. This new method of extraction is more cost effective and environmentally friendly than other methods.
Partner with us to license technology that treats corneal dysfunction without using donor transplants.
University of Melbourne researchers have created star-shaped polypeptides. Partner with us to accelerate this anti-bacterial technology.
Partner with us to accelerate the development of the graphene oxide foam, through licensing or direct investment.
Speed up development of this new pixel design, based on plasmonic nanostructures. It can detect the intensity of light across many wavelengths.
Partner with us to accelerate the development of the battery energy storage controller, through co-development or licensing.
Partner with us to develop the fabrication method for single crystal diamond membranes. Explore licensing and/or co-development opportunities.
Partner with us to develop and validate a method for producing polymer inclusion beads for ion extraction.
Partner with us to co-develop or license technology for producing low-cost catalysts.
New open-pit mining technology predicts landslides up to 15 days in advance. Talk to us about licensing or direct investment opportunities.
A company has recently partnered with us to develop a new pain treatment technology that blocks CCL17 expression. This treatment can improve pain for chronic conditions.
This severe asthma therapy enhances steroid activity, without autoimmune or cardiac toxicities. We have recently partnered with a start-up to speed up therapy development.